37 completed, 20 recruiting, 10 unknown, 9 terminated. 89 Phase 2, 11 Phase 1, 8 Phase 3.
Follow Mercaptopurine: new trials by email Literature Review of Mercaptopurine trials Research Report on Mercaptopurine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Not yet recruiting | SWOG Cancer Research Network | 90 | 2026-10-14 | 2026-10-13 |
| Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | Children's Oncology Group | 1708 | 2026-08-28 | 2026-07-30 |
| Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative B-ALL: A Prospective Umbrella Trial Inotuzumab Ozogamicin (IO), Venetoclax, Blinatumomab - Ph- Acute Lymphoblastic Leukemia (Ph-ALL) | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 32 | 2026-06-12 | 2026-06-11 |
| ALL Backbone in AYAs Blinatumomab, Oncaspar, Cyclophosphamide - Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Negative Lymphoblastic Leukemia | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 67 | 2026-04-03 | 2026-08-17 |
| Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Lymphoblastic Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 53 | 2025-10-10 | 2026-10-13 |
| Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 153 | 2025-06-05 | 2026-10-27 |
| A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) Biospecimen Collection, Blinatumomab, Bone Marrow Biopsy - B Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 222 | 2025-05-30 | 2026-10-27 |
| Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma Dexamethasone, Vincristine, Inotuzumab - Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 128 | 2025-01-23 | 2026-07-16 |
| Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) Dexamethasone, Vincristine, Daunorubicin - T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 100 | 2024-12-27 | 2026-08-10 |
| Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2024-08-09 | 2024-05-17 | |
| A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS Patients Hydroxyurea, Hydroxycarbamide, Valproic acid, 6-Mercaptopurine (6-MP) - Acute Myeloid Leukemia, Adult, Myelodysplastic Syndromes, Adult | Phase 1 / Phase 2 | Recruiting | Haukeland University Hospital | 48 | 2024-05-23 | 2025-06-29 |
| Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL Vincristine, Cyclophosphamide, Dexamethasone - Precursor Cell Lymphoblastic Leukemia-Lymphoma | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 53 | 2024-04-02 | 2025-12-17 |
| Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in Children induction: vincristine, L-asparaginase, dexamethasone, intrathecal Ara-C, intrathecal Methotrexate, Consolidation: Vincristine, Mecaptopurine, Intrathecal Methotrexate, Consolidation: Vincristine, Mecaptopurine, Cyclophosphamide, Cytarabine, L-asparaginase, Intrathecal Methotrexate - Lymphoblastic Leukemia in Children | Phase 2 | Recruiting | Hee Young Ju | 116 | 2024-03-05 | 2026-07-29 |
| TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II Dexamethasone, Mitoxantrone, PEG asparaginase - Lymphoblastic Leukemia | Phase 1 / Phase 2 | Recruiting | Tanja Andrea Gruber | 90 | 2023-11-03 | 2026-06-03 |
| Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia Cyclophosphamide, Vincristine, Blinatumomab - Leukemia | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 27 | 2023-07-14 | 2026-09-23 |
| Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic Leukemia Cyclophosphamide, Vincristine, Dexamethasone - B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma | Phase 2 | Active not recruiting | Alliance for Clinical Trials in Oncology | 68 | 2023-06-09 | 2026-07-10 |
| Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy Atezolizumab, 6-mercaptopurine, 6-thioguanine - Solid Tumor, Adult, Metastatic Cancer | Phase 1 / Phase 2 | Completed | Kristoffer Rohrberg | 18 | 2022-09-01 | 2026-01-14 |
| Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax Venetoclax, Navitoclax, Dexamethasone - Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Active not recruiting | St. Jude Children's Research Hospital | 35 | 2022-08-25 | 2026-10-15 |
| Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia Vincristine, Daunorubicin, Cyclophosphamide - Precursor Cell Lymphoblastic Leukemia-Lymphoma | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 100 | 2022-08-01 | 2025-08-01 |
| Efficacy and Safety of TMZ Plus 6-MP in the Patients With Recurrent Glioblastoma 6-mercaptopurine - Glioblastoma, Cancer | Phase 1 / Phase 2 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 27 | 2022-07-01 | 2024-02-28 |
Showing 20 of 89. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (47) · Leukemia (33) · Burkitt Lymphoma (16) · Leukemia, Biphenotypic, Acute (9) · Lymphoma (6) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (6) · Leukemia, T-Cell (3) · Neoplasms (3) · Down Syndrome (2) · Glioblastoma (2) · Leukemia, Myeloid, Acute (2) · Leukemia, Promyelocytic, Acute (2) · Lymphoma, Non-Hodgkin (2) · Neoplasm Metastasis (2) · Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (2)
National Cancer Institute (NCI) (12) · M.D. Anderson Cancer Center (11) · St. Jude Children's Research Hospital (10) · Children's Oncology Group (6) · Institute of Hematology & Blood Diseases Hospital, China (5) · SWOG Cancer Research Network (4) · Alliance for Clinical Trials in Oncology (3) · Dana-Farber Cancer Institute (2) · Gruppo Italiano Malattie EMatologiche dell'Adulto (2) · Nanfang Hospital, Southern Medical University (2) · Sun Yat-sen University (2) · City of Hope Medical Center (1) · Copenhagen University Hospital, Rigshospitalet (1) · Emory University (1) · Haukeland University Hospital (1)
United States (57) · Canada (14) · China (10) · Puerto Rico (10) · Australia (8) · Switzerland (4) · Denmark (3) · Germany (3) · Italy (3) · Netherlands (3) · Israel (2) · Japan (2) · Malaysia (2) · Singapore (2) · Spain (2)
Sima Jeha, MD (4) · Elias Jabbour (3) · Ibrahim Aldoss (2) · Wendy Stock, MD (2) · Albert Assad, MD (1) · Allen Eng Juh Yeoh, MBBS (1) · Allen Yeoh, MBBS (1) · Amir Fathi, MD (1) · Anjali S Advani (1) · Anne Angiolillo (1) · Barton Kamen, MD (1) · Carlos Rodriguez-Galindo, MD (1) · Cheryl L. Willman, MD (1) · Dan Douer, MD (1)
PMID 41671463, PMID 35622074, PMID 34048072, PMID 16105981, PMID 16556894, PMID 16809737, PMID 17136402, PMID 17170128, PMID 18156492, PMID 19648788, PMID 21623761, PMID 22210879, PMID 22488662, PMID 24475787, PMID 24516026, PMID 25526776, PMID 27171984, PMID 2758567, PMID 28859185, PMID 29352703, PMID 29812996, PMID 30658992, PMID 31813938, PMID 32330241, PMID 33054114, PMID 33191168, PMID 33242441, PMID 33245179, PMID 33496745, PMID 33858040, PMID 34120773, PMID 34492682, PMID 35675590, PMID 36279879, PMID 36322825, PMID 36545256, PMID 37131217, PMID 37187201, PMID 37276451, PMID 37753808, PMID 38551807, PMID 38867582, PMID 39158071, PMID 39468701, PMID 41619724, PMID 41692013, PMID 42154791, PMID 42166560
U10CA180886 (5), P30CA016672 (3), U10CA031946 (3), U10CA032102 (3), U10CA180888 (3), U10CA180821 (2), 2004 (1), 2009 (1), 2017 (1), 2019 (1), P30CA006973 (1), P30CA033572 (1), P30CA072720 (1), U01CA097452 (1), U10CA021115 (1)